TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22170412
Drug: Meloxicam (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meloxicam (10 mg once daily)
Study: 16080277
Drug: Gemfibrozil 900
Normalized name: gemfibrozil 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemfibrozil 900 mg tablet (test formulation)
Study: 16080277
Drug: Gemfibrozil 900
Normalized name: gemfibrozil 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemfibrozil 900 mg tablet (reference formulation)
Study: 11821720
Drug: Nifedipine GITS
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine GITS (30-60 mg)
Study: 8543496
Drug: Comparator agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator agents (cephalosporins, imipenem/cilastatin)
Study: 1771090
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg amitriptyline + 3 mg flupentixol
Study: 28688622
Drug: Atorvastatin 20mg
Normalized name: AMLODIPINE 5MG/ATORVASTATIN 20MG TAB
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin 20mg daily for 10 days (n=21)
Study: 28688622
Drug: Placebo 20mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 20mg daily for 10 days (n=23)
Study: 20435692
Drug: Metformin (BMI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (BMI > 32 kg/m(2))
Study: 20435692
Drug: Metformin (BMI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (BMI < or = 32 kg/m(2))
Study: 20435692
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (CC) (BMI < or = 32 kg/m(2))
Study: 20435692
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Metformin plus CC (BMI < or = 32 kg/m(2))
Study: 16237140
Drug: Protocol B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol B (CT at 90 kV with 100 mL contrast material)
Study: 16237140
Drug: Protocol C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol C (CT at 90 kV with 80 mL contrast material)
Study: 16237140
Drug: Protocol A
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol A (CT at 120 kV with 100 mL of contrast material)
Study: 12394963
Drug: Inhaled nitrogen
Normalized name: nitrogen Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitrogen oxide
Study: 2262581
Drug: Commercially available
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercially available toothpaste and gel products
Study: 31324862
Drug: Pyridostigmine 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridostigmine 0.25 mg/kg
Study: 22198441
Drug: Citalopram plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram plus omega-3 fatty acids (900 mg eicosapentaenoic acid, 200 mg docosahexaenoic acid, 100 mg other omega-3 fatty acids, two 1 g capsules twice daily)
Study: 22198441
Drug: Citalopram plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram plus placebo (olive oil, two 1 g capsules per day)
Study: 20528992
Drug: 1% silver
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% silver sulfadiazine, changed daily
Study: 12369079
Drug: Drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug treatment for capsaicin-induced coughing
Study: 9713448
Drug: L‐NAME 54
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐NAME 54 mg
Study: 9713448
Drug: L‐NAME 170
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐NAME 170 mg
Study: 7868876
Drug: Placebo (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1.5 ml/min saline) during exercise test
Study: 30575490
Drug: Modified FOLFIRINOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified FOLFIRINOX regimen (oxaliplatin 85 mg/m², irinotecan 180 mg/m², leucovorin 400 mg/m², fluorouracil 2400 mg/m² every 2 weeks for 24 weeks)
Study: 30575490
Drug: Gemcitabine (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (1000 mg/m² on days 1, 8, and 15 every 4 weeks for 24 weeks)
Study: 27056608
Drug: Intravenous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketamine (0.5 mg/kg of body weight), administered over 40 minutes, twice weekly for up to 4 weeks
Study: 27056608
Drug: Intravenous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketamine (0.5 mg/kg of body weight), administered over 40 minutes, thrice weekly for up to 4 weeks
Study: 27056608
Drug: Intravenous placebo,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous placebo, administered over 40 minutes, twice weekly for up to 4 weeks
Study: 27056608
Drug: Intravenous placebo,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous placebo, administered over 40 minutes, thrice weekly for up to 4 weeks
Study: 27056608
Drug: Open-label ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label ketamine (0.5 mg/kg of body weight), twice weekly
Study: 27056608
Drug: Open-label ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label ketamine (0.5 mg/kg of body weight), thrice weekly
Study: 18762639
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment for upper lumbar herniations (L2-L3 or L3-L4)
Study: 18762639
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment for L5-S1 herniations
Study: 18762639
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment for L4-L5 herniations
Study: 10535720
Drug: Imidapril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imidapril (5 mg daily for 3 to 6 months)
Study: 8767243
Drug: MAP maintained
Normalized name: phenazopyridine
DrugBank: Phenazopyridine (DB01438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MAP maintained above 70 mmHg using norepinephrine infusion (Group 2)
Study: 26848137
Drug: 100-300 mg
Normalized name: orchard grass pollen extract
DrugBank: Dactylis glomerata pollen (DB10379)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100-300 mg volanesorsen
Study: 24293339
Drug: Pharmaceutical care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical care (n = 315)
Study: 16947035
Drug: Patient evaluation
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient evaluation of treatment success
Study: 11463600
Drug: Low-dose theophylline
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose theophylline (250 mg twice per day)
Study: 9875685
Drug: Once-daily tobramycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily tobramycin (4 mg/kg/day)
Study: 9875685
Drug: Twice-daily tobramycin
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily tobramycin (4 mg/kg/day)
Study: 7742607
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose rate brachytherapy
Study: 7742607
Drug: Lower dose
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dose rate brachytherapy
Study: 17392726
Drug: Remifentanil 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 0.15 mcg/kg/min
Study: 30855722
Drug: Remifentanil 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 0.3 mcg/kg/min
Study: 28904310
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin (BTX) type A injections
Study: 21536199
Drug: Conservative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative therapy (control group)
Study: 23358983
Drug: Ciprofloxacin (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (750 mg twice daily) plus Amoxicillin/Clavulanic acid (1,000 mg twice daily)
Study: 23358983
Drug: Both arms
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both arms (Moxifloxacin and Combination Therapy)
Study: 21538382
Drug: Trimetazidine (TMZ)
Normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine (TMZ) monotherapy
Study: 19135286
Drug: Cholera vaccine
Normalized name: Cholera Vaccine
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholera vaccine coverage in the neighborhood
Study: 17587254
Drug: Weekly injected
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly injected subcutaneous interferon (IFN)‐beta‐1a 22 microg
Study: 15822545
Drug: Constraint-induced movement
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constraint-induced movement therapy (CIMT), 6 hours daily training for 2 weeks
Study: 15822545
Drug: Conservative treatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment, bimanual-upper-extremity training for 2 weeks
Study: 10896237
Drug: Manual dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual dosing using a locally defined algorithm
Study: 4028632
Drug: Oral activated
Normalized name: activated charcoal Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral activated charcoal (180 gm) in divided doses over 24 hours
Study: 27499018
Drug: Taliglucerase alfa
Normalized name: Taliglucerase alfa
DrugBank: Taliglucerase alfa (DB08876)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Taliglucerase alfa dose adjusted
Study: 28132725
Drug: Lower protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower protein intake (g/kg/day)
Study: 26687836
Drug: Standard-dose imatinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose imatinib
Study: 17452544
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy post-AMI
Study: 8665034
Drug: FK224 (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: FK224 (4 mg)
Study: 2062984
Drug: d-amphetamine 30
Normalized name: dextroamphetamine
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-amphetamine 30 mg
Study: 2062984
Drug: d-amphetamine (3.75,
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-amphetamine (3.75, 7.5, 15 and 30 mg)
Study: 2062984
Drug: methylphenidate (7.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: methylphenidate (7.5, 15, 30 and 60 mg)
Study: 2062984
Drug: diazepam (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: diazepam (5, 10, 20 and 40 mg)
Study: 3964335
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg N-butylscopolaminium bromide (Buscopan)
Study: 3964335
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg N-butylscopolaminium bromide (Buscopan)
Study: 25616100
Drug: Pharmacogenomic-guided warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacogenomic-guided warfarin treatment
Study: 25616100
Drug: Non-PGx therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-PGx therapy (control)
Study: 11012478
Drug: Ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine bismuth citrate 400 mg b.d. on days 1-5, plus amoxycillin 1 g b.d., clarithromycin 500 mg b.d. and metronidazole 500 mg b.d. on days 3-5 (RACM)
Study: 11012478
Drug: Ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine bismuth citrate 400 mg b.d. plus amoxycillin 1 g b.d. and clarithromycin 500 mg b.d. for 10 days (RAC)
Study: 11012478
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg o.m. plus amoxycillin 1 g b.d. and clarithromycin 500 mg b.d. for 10 days (OAC)
Study: 11012478
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg o.m. on days 1-5, plus amoxycillin 1 g b.d., clarithromycin 500 mg b.d. and metronidazole 500 mg b.d. on days 3-5 (OACM)
Study: 1728612
Drug: Conventional radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional radiotherapy or chemotherapy after surgery
Study: 6731670
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg albendazole with a meal
Study: 6731670
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg albendazole 3 or more hours after or before a meal
Study: 31941574
Drug: Interventions based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interventions based on positive psychology, supportive-expressive group therapy, behavioral therapy, or mindfulness
Study: 27411698
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro injected into lipohypertrophic tissue (LHT)
Study: 27411698
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro injected into normal adipose tissue (NAT)
Study: 16276244
Drug: Combination drug
Normalized name: combination drugs used in erectile dysfunction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination drug therapy aimed at raising HDL-cholesterol
Study: 16276244
Drug: Niacin and
Normalized name: My Favorite Niacin and Inositol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niacin and well-tolerated fibrates as adjunct to statins or primary therapy
Study: 2569309
Drug: Diuretic (xipamide-triamterene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic (xipamide-triamterene combination, Neotri)
Study: 28252269
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion sonography (SIS) followed by Pipelle® sampling
Study: 28252269
Drug: Pipelle® sampling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pipelle® sampling followed by saline infusion sonography (SIS)
Study: 26590673
Drug: Nintedanib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nintedanib (200 mg twice daily on days 2-21 of every 3-week cycle for up to 120 weeks)
Study: 26590673
Drug: Placebo (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (twice daily on days 2-21 of every 3-week cycle for up to 120 weeks)
Study: 22338103
Drug: E/S +
Normalized name: Estradiol/Norethindrone Acetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: E/S + extended-release niacin (N; titrated to 2 g)
Study: 19776570
Drug: Rinsing with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rinsing with 20 ml of 100 mg F/l NaF mouthwash after brushing with fluoridated toothpaste (Regime B)
Study: 19776570
Drug: Brushing with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brushing with 1 g of 1,450 microg F/g NaF toothpaste followed by rinsing for 5 s with 10 ml water (Regime A)
Study: 11835723
Drug: Moderate hypothermia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate hypothermia therapy (MHT) for 4-10 days
Study: 11835723
Drug: Moderate hypothermia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate hypothermia therapy (MHT)
Study: 2889460
Drug: Xamoterol 200
Normalized name: xamoterol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xamoterol 200 mg orally once daily
Study: 2889460
Drug: Xamoterol 400
Normalized name: Xamoterol
DrugBank: Xamoterol (DB13781)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xamoterol 400 mg orally once daily
Study: 2889460
Drug: Xamoterol 600
Normalized name: Xamoterol
DrugBank: Xamoterol (DB13781)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xamoterol 600 mg orally once daily
Study: 2889460
Drug: Xamoterol (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xamoterol (all doses)
Study: 29544720
Drug: 100 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 μg of morphine (M100)
Study: 29544720
Drug: 200 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 μg of morphine (M200)
Study: 22890714
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) infusion in older sedentary individuals (OS)
Study: 22890714
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) infusion in older active individuals (OA)
Study: 22890714
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) infusion in young sedentary individuals (Y)
Study: 20135144
Drug: Spray bottle
Normalized name: Povidone-Iodine 100 mg in 1 mL TOPICAL SOLUTION [Prep SolutionWith Spray Bottle]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spray bottle (SB)
Study: 18056004
Drug: G-CSF from
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF from day 6 after induction chemotherapy
Study: 18056004
Drug: G-CSF from
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF from day 12 after induction chemotherapy
Study: 12127639
Drug: Intra-amniotic injection
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-amniotic injection of 40 mg PGF2alpha
Study: 12127639
Drug: Intravaginal application
Normalized name: taurolidine
DrugBank: Taurolidine (DB12473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravaginal application of 200 mcg misoprostol (12 hourly doses, max 4 doses)
Study: 630793
Drug: Chlorpromazine (CPZ)
Normalized name: Chlorpromazine
DrugBank: Chlorpromazine (DB00477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorpromazine (CPZ) 100 mg with concurrent lithium therapy (900 mg/day for 7 days)
Study: 630793
Drug: Chlorpromazine (CPZ)
Normalized name: Chlorpromazine
DrugBank: Chlorpromazine (DB00477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorpromazine (CPZ) 100 mg without concurrent lithium therapy
Study: 19624698
Drug: Intervention schools
Normalized name: cetylpyridinium chloride Topical Spray [Rocco's Old School]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention schools (oral health promotion programme)
Study: 9660419
Drug: Standard long
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard long protocol of SC leuprolide acetate (group L)
Study: 9660419
Drug: Monthly injection
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly injection of leuprolide acetate depot for 4 months (group D)
Study: 9660419
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (L and D)
Study: 8005563
Drug: Pirenzepine (PZ)
Normalized name: pirenzepine
DrugBank: Pirenzepine (DB00670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine (PZ) low dose (50 mg at 22 h)
Study: 8005563
Drug: Pirenzepine (PZ)
Normalized name: pirenzepine
DrugBank: Pirenzepine (DB00670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine (PZ) high dose (50 mg at 8 h plus 100 mg at 22 h)
Study: 805388
Drug: Verapamil 240
Normalized name: verapamil 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 240 mg per day
Study: 11422755
Drug: Captopril (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (average 74 mg/day, range 12.5 to 125 mg/day)
Study: 11422755
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no treatment with captopril)
Study: 8996291
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus ticlopidine (antiplatelet therapy)
Study: 8996291
Drug: Intense anticoagulant
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intense anticoagulant therapy (control)
Study: 31977833
Drug: Energy gel
Normalized name: Senergy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Energy gel ingestion every 30 minutes (T1)
Study: 31977833
Drug: Energy gel
Normalized name: Senergy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Energy gel ingestion every 45 minutes (T2)
Study: 31977833
Drug: No gel
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No gel ingested during exercise (T3)
Study: 25319120
Drug: Canrenone 50
Normalized name: canrenone
DrugBank: Canrenone (DB12221)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canrenone 50 mg once a day for 3 months, then 50 mg twice a day
Study: 23165696
Drug: GEn 1800
Normalized name: GEN-001
DrugBank: GEN-001 (DB17518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GEn 1800 mg
Study: 23165696
Drug: GEn 2400
Normalized name: GEN-001
DrugBank: GEN-001 (DB17518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GEn 2400 mg
Study: 23165696
Drug: GEn 3000
Normalized name: Epogen 3000 UNT/ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: GEn 3000 mg
Study: 18469255
Drug: Daidzein-7-O-beta-d-glucoside (DG)
Normalized name: trans-resveratrol 3-O-β-D-glucoside
DrugBank: Polydatin (DB11263)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daidzein-7-O-beta-d-glucoside (DG) (1 mg DAI aglycone equivalent/kg body weight)
Study: 18469255
Drug: Daidzein (DAI)
DrugBank: Daidzein (DB13182)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daidzein (DAI) (1 mg DAI aglycone equivalent/kg body weight)
Study: 12587824
Drug: High avidity
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High avidity anti-dsDNA antibodies in SLE patients
Study: 12587824
Drug: ELISA method
Normalized name: pseudopterogorgia elisabethae extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: ELISA method for anti-dsDNA antibody avidity determination
Study: 12560163
Drug: Human insulin
Normalized name: Human insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human insulin 30/70
Study: 9417494
Drug: Sodium selenite
Normalized name: Sodium selenite
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Sodium selenite treatment over a period of 28 days
Study: 8338056
Drug: Intensive neoadjuvant
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive neoadjuvant chemotherapy regimen (FEC-HD) repeated every 21 days
Study: 8338056
Drug: Intensive neoadjuvant
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive neoadjuvant chemotherapy regimen (FEC-HD)
Study: 8338056
Drug: Intensive neoadjuvant
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive neoadjuvant chemotherapy regimen (FEC-HD) followed by modified radical mastectomy or radiotherapy
Study: 3552076
Drug: Discontinue all
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Discontinue all treatment after 8 months of maintenance chemotherapy